Audentes Therapeutics, Inc. (NASDAQ:BOLD) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday.

According to Zacks, “Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company’s product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California. “

Several other equities research analysts have also recently commented on BOLD. Leerink Swann initiated coverage on Audentes Therapeutics in a research note on Monday, May 1st. They set an “outperform” rating and a $22.00 target price for the company. Wedbush reissued an “ourperform” rating and issued a $20.00 price objective on shares of Audentes Therapeutics in a research note on Monday, May 15th. Finally, ValuEngine raised Audentes Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 20th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Audentes Therapeutics has an average rating of “Buy” and a consensus target price of $22.25.

Audentes Therapeutics (NASDAQ BOLD) traded up 4.03% during trading on Tuesday, hitting $20.63. The stock had a trading volume of 103,460 shares. The company’s market cap is $571.99 million. The company has a 50-day moving average of $19.39 and a 200 day moving average of $16.61. Audentes Therapeutics has a 52 week low of $13.06 and a 52 week high of $22.82.

Audentes Therapeutics (NASDAQ:BOLD) last released its earnings results on Thursday, May 11th. The biotechnology company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.09. On average, equities research analysts anticipate that Audentes Therapeutics will post ($3.33) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/08/08/audentes-therapeutics-inc-bold-downgraded-to-hold-at-zacks-investment-research.html.

In other Audentes Therapeutics news, CEO Matthew R. Patterson sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 13th. The stock was sold at an average price of $20.00, for a total value of $300,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Matthew R. Patterson sold 2,850 shares of the firm’s stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $20.00, for a total value of $57,000.00. The disclosure for this sale can be found here. Insiders sold 32,850 shares of company stock valued at $653,700 in the last three months. Insiders own 47.30% of the company’s stock.

A number of large investors have recently made changes to their positions in BOLD. Jennison Associates LLC boosted its position in shares of Audentes Therapeutics by 182.4% in the second quarter. Jennison Associates LLC now owns 846,273 shares of the biotechnology company’s stock valued at $16,189,000 after buying an additional 546,617 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Audentes Therapeutics by 180.7% in the second quarter. Bank of New York Mellon Corp now owns 52,900 shares of the biotechnology company’s stock valued at $1,012,000 after buying an additional 34,057 shares during the last quarter. State of Wisconsin Investment Board bought a new position in shares of Audentes Therapeutics during the second quarter valued at about $210,000. Rhumbline Advisers bought a new position in shares of Audentes Therapeutics during the second quarter valued at about $252,000. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Audentes Therapeutics by 139.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 25,600 shares of the biotechnology company’s stock valued at $490,000 after buying an additional 14,900 shares during the last quarter. 57.52% of the stock is owned by hedge funds and other institutional investors.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Get a free copy of the Zacks research report on Audentes Therapeutics (BOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.